Show simple item record

dc.contributor.authorO'Sullivan, Brian P.
dc.contributor.authorFlume, Patrick
dc.date2022-08-11T08:10:14.000
dc.date.accessioned2022-08-23T17:00:36Z
dc.date.available2022-08-23T17:00:36Z
dc.date.issued2009-09-18
dc.date.submitted2012-01-11
dc.identifier.citationSemin Respir Crit Care Med. 2009 Oct;30(5):505-13. Epub 2009 Sep 16. <a href="http://dx.doi.org/10.1055/s-0029-1238909">Link to article on publisher's site</a>
dc.identifier.issn1069-3424 (Linking)
dc.identifier.doi10.1055/s-0029-1238909
dc.identifier.pmid19760538
dc.identifier.urihttp://hdl.handle.net/20.500.14038/43829
dc.description.abstractThere is strong evidence that early, aggressive therapy of lung disease leads to improved quality and quantity of life for patients with cystic fibrosis (CF). The treatment of pulmonary disease associated with CF is multifactorial, encompassing prophylaxis, aggressive treatment of infection, use of antiinflammatory agents, and treatment of severe complications. Chest physiotherapy on a regular basis, perhaps using new modalities that allow patient autonomy, is also crucial. This review covers the pathogenesis of CF lung disease and current approaches to therapy, highlighting guidelines recently published by the Cystic Fibrosis Foundation. Clinicians caring for patients with CF should maximize current therapies with the goal of preserving lung function until the time a more definitive curative or controller medication is developed. Empowering patients in the process of providing their own care is a key to achieving this goal.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=19760538&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1055/s-0029-1238909
dc.subjectCystic Fibrosis
dc.subjectHumans
dc.subjectLung Diseases
dc.subjectPersonal Autonomy
dc.subjectPractice Guidelines as Topic
dc.subjectQuality of Life
dc.subjectRespiratory Function Tests
dc.subjectRespiratory Therapy
dc.subjectRespiratory Tract Infections
dc.subjectAllergy and Immunology
dc.subjectPediatrics
dc.subjectRespiratory Tract Diseases
dc.titleThe clinical approach to lung disease in patients with cystic fibrosis
dc.typeJournal Article
dc.source.journaltitleSeminars in respiratory and critical care medicine
dc.source.volume30
dc.source.issue5
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/peds_pulmonary/43
dc.identifier.contextkey2441404
html.description.abstract<p>There is strong evidence that early, aggressive therapy of lung disease leads to improved quality and quantity of life for patients with cystic fibrosis (CF). The treatment of pulmonary disease associated with CF is multifactorial, encompassing prophylaxis, aggressive treatment of infection, use of antiinflammatory agents, and treatment of severe complications. Chest physiotherapy on a regular basis, perhaps using new modalities that allow patient autonomy, is also crucial. This review covers the pathogenesis of CF lung disease and current approaches to therapy, highlighting guidelines recently published by the Cystic Fibrosis Foundation. Clinicians caring for patients with CF should maximize current therapies with the goal of preserving lung function until the time a more definitive curative or controller medication is developed. Empowering patients in the process of providing their own care is a key to achieving this goal.</p>
dc.identifier.submissionpathpeds_pulmonary/43
dc.contributor.departmentDepartment of Pediatrics
dc.source.pages505-13


This item appears in the following Collection(s)

Show simple item record